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We reviewed the medical records of all patients evaluated at our
hypertension clinic from 2009 to 2012 who met the deﬁnition of
RH (3). The TDM was performed in 56 subjects in whom all
antihypertensive drugs prescribed were titrated to the maximal or
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835patients did not undergo TDM, because of submaximal dosages
of 1 of the antihypertensive drugs. Subjects with serum levels of
at least 1 prescribed antihypertensive drug below the minimal
detection limit were considered to be nonadherent. Nonadherent
patients were younger (age 49  2 years vs. 56  2 years, p < 0.05)
and had higher baseline diastolic BP (103  4 mm Hg vs. 84  2
mm Hg, p < 0.05) and heart rate (83  3 beats/min vs. 71  3
beats/min, p < 0.05) than adherent patients. Systolic blood pres-
sure (SBP) was similar between the 2 groups (169  7 mm Hg vs.
166  5 mm Hg, p ¼ NS).
Over one-half (54%) of patients who underwent TDM were
found to be nonadherent to treatment. Speciﬁcally, 18 (32%) had
undetectable levels of all drugs (Fig. 1B), whereas 12 (22%) had
at least 1 undetectable drug. All 30 nonadherent patients initially
denied missing any doses of their antihypertensive medications
in the 24 h before TDM.
After the initial visit, 16 subjects in the nonadherent group, 16
in the adherent group, and 87 in the untested group completed
follow-up visits. When the 16 patients in the nonadherent group
were provided with TDM results, 2 attributed their nonadherence
to memory loss, 3 described debilitating fatigue not previously
reported during the ﬁrst encounter, and 5 reported drug cost as
a major barrier to nonadherence. Additional counseling of
methods to overcome barriers to adherence was provided to the
patients during the ﬁrst follow-up visit, and BP reduced from the
initial visit to the second follow-up visit by 46 10/26 14 mmHg
in the nonadherent group, compared with 12  17/7  7 mm Hg
in the adherent group and 11  4/4  2 mm Hg in the untested
group (p < 0.01 for both SBP and diastolic BP) (Fig. 1C). No
differences in the number of antihypertensive medications were
found during the second follow-up visit among the 3 groups (5.3 
0.7 vs. 4.2  0.4 vs. 3.7  0.2 drugs, respectively, p > 0.05).
The median cost of TDM in the nonadherent group was
$301.00 ($224.00 to $544.00)/subject, which was not signiﬁcantly
different from $277.00 ($140.00 to $375.00)/subject in the adherent
group (p ¼ 0.2). The incremental cost associated with TDM in
the tested group (regardless of TDM result) was $4.90 ($3.80 to
$5.90)/mm Hg-reduction in SBP. Long-term results were avail-
able in a subset of 5 RH patients who were initially nonadherent
to treatment. The TDM-guided adherence counseling led to
sustained reduction in BP (from 200  13/121  8 mm Hg to
117  13/75  6 mm Hg) over an average of 25  4 months
of follow-up. This improvement in BP was achieved without
increasing the number of antihypertensive drugs prescribed (5.6 
0.4 drugs vs. 4.6  0.7 drugs). Repeated TDM in 9 initially unde-
tectable drugs in these 5 patients revealed therapeutic serum levels in
all drugs.
Nonadherence to antihypertensive medications is a major cause
of cardiovascular morbidity and mortality. However, practical
methods of adherence detection are not well-developed, and
methods to modify nonadherent behavior have so far been unsat-
isfactory. Many physicians might not be aware that TDM of
antihypertensive drug levels is available for clinical use and is
covered by most health insurance plans. The advantage of this
technique is ease of use without requiring additional time spent
tracking the pharmacy reﬁll rates or pill counts.
More importantly,whenpatientswere informedof their undetectable
serum drug levels and provided additional counseling, BP control was
markedly improved without increasing treatment intensity. We found
the incremental cost of TDM testing/mm Hg-reduction in SBP tobe under $5.00/mm Hg-reduction in BP, far less than the cost
associated with device therapies such as renal sympathetic
denervation (RDN). The cost of RDN in European countries
was estimated to be V4,500.00 or approximately $185.00/mm Hg-
reduction in SBP at current exchange rates assuming an average
reduction in SBP of 33 mm Hg with RDN (4).
Our study is limited by retrospective design and small sample
size, which might, for example, explain our inability to demon-
strate a statistically signiﬁcant difference in SBP between adherent
and nonadherent groups at baseline. Nonetheless, our data sug-
gest TDM is a useful and practical tool in both monitoring
adherence and in facilitating BP control in patients with appar-
ently resistant hypertension at a favorable incremental cost.
Further large prospective studies with long-term follow-up are
still needed to conﬁrm the beneﬁt effect of TDM on BP control
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